trending Market Intelligence /marketintelligence/en/news-insights/trending/fjpoi7ldb3mfgojjqgkhoa2 content esgSubNav
In This List

Israel's Alpha Tau secures $29M in financing for cancer treatment

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Israel's Alpha Tau secures $29M in financing for cancer treatment

Alpha Tau Medical Ltd., a privately held cancer therapy developer in Israel, secured $29 million in a funding round led by Shavit Capital.

Participants of the funding round also include equity crowdfunding platform OurCrowd.com, Medison Ltd.'s venture capital arm Medison Ventures, and private equity investors Ronald Cohen and Alan Patricof, founders of Apax Partners.

"The funding will be invaluable to explore the full potential of the Alpha DaRT as a cancer treatment for clinical trials worldwide," Alpha Tau CEO Uzi Sofer said in a news release.

Alpha DaRT is the company's radiation-based cancer treatment. Alpha Tau is evaluating the technology in patients with pancreatic cancer, breast cancer, gynecological cancer, prostate cancer as well as head and neck cancer.